Dear All, Our colleagues in Europe have been busy! Along with yesterday’s announcement about transferrable exclusivity vouchers, we also had publication of the Horizon Europe Work Programme 2026-2027. It’s a really big program that includes within its Cluster 1 a trio of calls of interest to readers of this newsletter: HORIZON-HLTH-2027-01-DISEASE-08 call seeks projects developing
Dear All, There are more details yet to come, but the EU Council (“the Council”) and the EU Parliament (EP) yesterday announced an agreement on the update to the EU General Pharmaceutical Legislation that includes transferable exclusivity vouchers (TEVs or TEEVs, depending on your preferred abbreviation). Here’s the key text from the EP’s press release:
Note: As always, please use the copy of the newsletter posted at https://amr.solutions/ if you have trouble with links in this newsletter. Dear All, As I hope you know from the meeting calendar in this newsletter, the 2nd edition of GAMRIC, the Global AMR Innovators Conference, will be 22-24 Sep 2026 in Lisbon, Portugal. Although only the 2nd year
Dear All, The 8 Dec 2025 newsletter entitled “Phage therapy: Regulatory perspectives from TATFAR” generated a fair bit of commentary! I’ve now added several post-newsletter addenda to the online copy of the newsletter and I thought the amount of new material warranted a summary of same via this follow-up newsletter. If I’ve missed a resource,
Dear All, Integrating perspectives from EC HERA, EMA, Health Canada, Norway, UK MHRA, US FDA, and US NIH, the Transatlantic Task Force on AMR (TATFAR)’s Phage Working Group have just published a detailed summary of information on phage therapy with particular focus on its regulatory aspects. Here are the links you need: [key paper for this
Dear All (with thanks to Vega Masignani for co-authoring this newsletter), While the work needed to create new antibacterial agents is the primary topic of this newsletter, the need for vaccines of all types is definitely part of our community’s joint remit. As discussed in the 29 Mar 2021 newsletter (“Vaccines to turn back the
See also This related newsletter: 14 Jul 2022, entitled “WHO Vaccine Pipeline Review; CDC On Impact Of COVID On AMR.” This 20 Oct 2024 report from WHO: “Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use: technical report” This 25 Apr 2024 paper in Lancet Global Health by Hausdorff and colleagues: “Facilitating
Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research (ICMR) released its report on AMR across India for 2024. The report is the eighth since AMRSRN started publishing such reports in 2017; the report for 2024 is here and links to all the prior reports
Dear All, WHO have just (2 Oct 2025) released a pair of reports on therapeutics and diagnostics for bacterial pathogens, with a focus on how these advance our tools for priority bacterial pathogens. Here are the links you need: WHO 2025 update on the preclinical and clinical antibacterial pipeline Title: “Analysis of antibacterial agents in
Dear All, Recently posted, six concepts were approved for FY 2027 funding at the September 2025 meeting of NIAID’s Division of Microbiology and Infectious Diseases (DMID). These are not yet published as official calls for applications, but it’s reasonable to expect that these concepts will be funded and the advance notice allows anyone interested to start thinking: Infectious